StockNews.AI
BX
StockNews.AI
138 days

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront

1. Novartis acquires Anthos Therapeutics for $3.1 billion, co-founded by Blackstone. 2. This acquisition signifies value creation for Blackstone's healthcare investments.

M&A
-6.06%Current Return
VS
-5.85%S&P 500
$133.104/03 05:33 PM EDTEvent Start
$125.0404/04 11:49 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition suggests strong valuation increases for Blackstone's investments, akin to other successful exits. Historical acquisitions in biotech often lead to stock price gains for investors involved.

How important is it?

The acquisition reflects Blackstone's effective investment strategy in healthcare, likely enhancing BX's market perception and driving future investments.

Why Long Term?

As Anthos expands under Novartis, Blackstone may see sustained revenue and value growth over several years, similar to long-term biotech trends post-acquisition.

Related Companies

NVSBX
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture,.

Related News